February 23, 2016
Shionogi said on February 22 that its investigational agent naldemedine (development code: S-297995) significantly improved opioid-induced constipation versus placebo in a PIII clinical study dubbed COMPOSE I. The drug is the company’s first product being developed simultaneously in the US,...read more